Treatment outcomes with pegylated interferon and ribavirin for male prisoners with chronic Hepatitis C

Journal of Clinical Gastroenterology

Volumn 43, Issue 7, 2009, Pages 686-691

  Chew, Kara W ^a   Allen, Scott A ^b   Taylor, Lynn E ^b   Rich, Josiah D ^b   Feller, Edward ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

Chronic hepatitis C; Liver disease; Pegylated interferon; Prisoners

Indexed keywords

AMINOTRANSFERASE; ANTIDEPRESSANT AGENT; HEMOPOIETIC GROWTH FACTOR; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS ANTIBODY; VIRUS RNA;

ADULT; AFRICAN AMERICAN; ANEMIA; ANTIBODY SCREENING; ARTICLE; COHORT ANALYSIS; DEPRESSION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG WITHDRAWAL; EUROPEAN AMERICAN; FATIGUE; FOLLOW UP; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MENTAL DISEASE; MUSCULOSKELETAL DISEASE; NEUTROPENIA; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; PRISON; RISK FACTOR; SIDE EFFECT; SUICIDAL IDEATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; WEIGHT REDUCTION;

ADULT; AFRICAN AMERICANS; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FOLLOW-UP STUDIES; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PRISONERS; RETROSPECTIVE STUDIES; RHODE ISLAND; RIBAVIRIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 68949157054     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCG.0b013e31818dd94c     Document Type: Article

References (31)

1. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N EnglJ Med. 1999;341:556-562.
2. Edlin BR. Five million Americans infected with the hepatitis C virus: a corrected estimate. American Association for the Study of Liver Diseases Annual Meeting, Abstract 44. San Francisco, CA. November 2005.
3. Strader DB, Wright T, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004;39: 1147-1171.
4. Scientific Registry of Transplant Recipients. 2004 OPTN/ SRTR Annual Report: Transplant Data 1993-2004. HHS/ HRSA/SPB/DOT; UNOS; URREA. (Chapter VII).
5. Kim WR. The burden of hepatitis C in the United States. Hepatology. 2002;36:S30-S34.
6. Weinbaum C, Lyerla R, Margolis HS. Prevention and control of infections with hepatitis viruses in correctional settings. Centers for Disease Control and Prevention. MMWR Recomm Rep. 2003;52:1-36.
7. Macalino GE, Vlahov D, Seanford-Colby S, et al. Prevalence and incidence of HIV, hepatitis B virus, and hepatitis C virus infections among males in Rhode Island Prisons. Am J Public Health. 2004;94:1218-1223.
8. Hammett TM, Harmon MP, Rhodes W. The burden of infectious disease among inmates of and releases from US correctional facilities 1997. Am J Public Health. 2002;92:1789-1794.
9. Baillargeon J, Soloway R, Paar D, et al. End-stage liver disease in a state prison population. Ann Epidemiol. 2007; 10: 808-813.
10. Spaulding A, Greene C, Davidson K, et al. Hepatitis C in state correctional facilities. Prev Med. 1999;28:92-100.
11. Falck-Ytter Y, Kale H, Mullen KD, et al. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med. 2002; 136:288-292.
12. Koretz RL. Hepatitis C-the case against treatment. Eur J Surg Suppl. 2001; 167:34-39.
13. NIH Consensus Statement. Management of hepatitis C: 2002. June 10-12, 2002. http://www.consensus.nih.gov.
14. Hammett TM. Making the case for health interventions in correctional facilities. J Urban Health. 2001;78:236-240.
15. Spaulding AC, Weinbaum CM, Lau DT, et al. A framework for management of hepatitis C in prisons. Ann Intern Med. 2006;144:762-769.
16. De Groot AS, Stubblefield E, Bick J. Hepatitis C: a correctional-public health opportunity. Medscape Infect Dis. 2001 ;3:1-14. ( www.medscape.com/ viewarticle/408298).
17. Allen SA, Spaulding AC, Osei AM, et al. Treatment of chronic hepatitis C in a state correctional facility. Ann Intern Med. 2003;138:187-190.
18. Sterling RK, Hofmann CM, Luketic VA, et al. Treatment of chronic hepatitis C virus in the Virginia Department of Corrections: can compliance overcome racial differences to response. Am J Gastroenterol. 2004;99:866-872.
19. Farley J, Vasdev S, Fischer B, et al. Feasibility and outcome of HCV treatment in a Canadian Federal Prison Population. Am J Public Health. 2005;95:1737-1739.
20. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958-968.
21. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-982.
22. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346-355.
23. Sabbatani S, Giuliani R, Manfredi R. Combined pegylated interferon and ribavirin for the management of chronic hepatitis C in a prison setting. Braz J Infect Dis. 2006; 10:274-278.
24. Maru DS, Bruce RD, Basu S, et al. Clinical outcomes of hepatitis C treatment in a prison setting: feasibility and effectiveness for challenging treatment populations. Clin Infect Dis. 2008;47:952-961.
25. Shiffman ML, Di Bisceglie AM, Lindsay KL. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who failed prior treatment. Gastroenterology. 2004;126:1015-1023.
26. Parise E, Cheinquer H, Crespo D, et al. Peginterferon alfa-2a (40KD) (PEGASYSs) plus ribavirin (COPEGUSs) in retreatment of chronic hepatitis C patients, nonresponders and relapsers to previous conventional interferon plus ribavirin therapy. Braz J Infect Dis. 2006;10:1 1-16.
27. Goncales FL Jr, Vigani A, Goncales N, et al. Weight-based combination therapy with peginterferon alpha-2b and ribavirin for naive, relapse and non-responder patients with chronic hepatitis C. Braz J Infect Dis. 2006;10:311-316.
28. Daniel S. Chronic hepatitis C treatment patterns in African American patients: an update. Am J Gastroenterol. 2005;100: 716-722.
29. Muir AJ, Bornstein JD, Killenberg PF, et al. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med. 2004;350:2265-2271.
30. Jeffers LJ, Cassidy W, Howell CD, et al. Peginterferon alfa-2a (40 kd) and ribavirin for Black American patients with chronic HCV genotype 1. Hepatology. 2004;39:1702-1708. (Pubitemid 38702672)
31. Conjeevaran HS, Fried MW, Jeffers LJ, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology. 2006;131:470-477.